CN105451749B - 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 - Google Patents

吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 Download PDF

Info

Publication number
CN105451749B
CN105451749B CN201480037596.0A CN201480037596A CN105451749B CN 105451749 B CN105451749 B CN 105451749B CN 201480037596 A CN201480037596 A CN 201480037596A CN 105451749 B CN105451749 B CN 105451749B
Authority
CN
China
Prior art keywords
treatment
vitamine
prevention
active metabolite
adsorb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480037596.0A
Other languages
English (en)
Other versions
CN105451749A (zh
Inventor
瓦莱里·I·斯特罗科夫
米哈伊尔·D·普罗霍罗夫
奥莉加·约内斯-斯特鲁科瓦
维亚切斯拉夫·N·特里弗诺夫
尤利娅·A·叶利斯特拉托娃
康斯坦丁·G·叶利斯特拉托夫
纳塔利娅·V·库鲁斯
纳塔利娅·V·叶列米纳
玛丽娜·N·马克西莫瓦
拉姆济亚·T·加列耶瓦
拉里莎·G·拉琴科
亚历山大·V·费奥多罗夫
叶夫根尼·N·克鲁佳科夫
塔季扬娜·V·叶利斯特拉托娃
伊琳娜·V·霍米亚科瓦
加林娜·A·托尔宾纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
"PARAFARM"
Parafarm OOO
Original Assignee
Parafarm OOO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parafarm OOO filed Critical Parafarm OOO
Publication of CN105451749A publication Critical patent/CN105451749A/zh
Application granted granted Critical
Publication of CN105451749B publication Critical patent/CN105451749B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明涉及药物，具体涉及达到关于与多种形式的卡他性疾病相关的状态的治疗和预防效果的方法，且还涉及增强免疫力的方法。

Description

吸附雄蜂幼虫匀浆和维生素D3或D族维生素和/或其活性代谢 物在病毒性疾病的预防和治疗中的应用
本发明涉及药物，尤其涉及用于与多种形式的卡他性疾病相关的病状的预防和治疗的试剂，也涉及用于免疫力增强的试剂。
已知吸附雄峰幼虫匀浆和维生素D3或其他D族维生素(和/或它们的活性代谢物)被用于封闭干骺端(小梁)骨部分形成的空腔，以及被用于预防那里的钙流失，这样使得骨空腔减小和消除，并且预防所述骨空腔的形成(专利RU2466732，2011年05月31日)。
在进行上述“骨-维生素D3(Osteo-vit D3)”用于骨组织过度矿化的预防和治疗的研究时(于2012-2013年期间)，在接受该制剂的患者中未发现呼吸道病毒性疾病，尤其是流行性感冒的病例。此外，在接受上述制剂的患者中发现改善的一般健康状况和免疫力。
在这些研究期间，没有发现能达到上述效果的具有相似组成的其他药物。
因此，由于所述已知药物(吸附雄峰幼虫匀浆和维生素D3或其他D族维生素和/或它们的活性代谢物)的施用，发现实现一项新的技术成果，即：卡他性疾病和呼吸道病毒性疾病的预防和治疗。
该技术成果的实现归因于每日摄入10mg至1000mg的吸附雄峰幼虫匀浆和50ME至100,000ME的维生素D3或D族维生素(和/或它们的活性代谢物)。
所要求保护的药物的宽剂量范围由患者的个体特征阐明，所述个体特征为年龄、饮食、生活方式、种族、居住国家、性别、遗传和既往疾病。通过评估这些标准，医生选择所要求保护的药物组分的个体剂量，并基于治疗动态作出修正。
实施例1
在由22名年龄从32岁至68岁(其中9名为男性，13名为女性)的患者组成的组中进行所述制剂有效性的研究。所述患者在一年三次，每次三个月，间隔一个月的疗程中，通过口服或舌下给药接受每日两次每次1片的所述制剂，以确定所述制剂对于卡他性疾病和呼吸道疾病的防护效力。
研究结果为，在对上述组进行6个月的治疗后，临床观察到免疫力增强，其通过客观检查数据确认：在秋季和冬季期间，在所述患者中没有急性呼吸道疾病或流行性感冒的病例。
实施例2
在上述研究后进行了额外的研究。由年龄从21岁至59岁，患有初期流行性感冒的9名患者(他们中4名为男性，5名为女性)组成的组，通过舌下给药于1个月内接受每天两次每次1片的上述制剂。
结果为，在研究组的患者中，病毒性呼吸道疾病的急性阶段的表现症状没有发展：没有出现发烧、头痛、寒战和流鼻涕。没有例如支气管炎的并发症。
实施例3
对11名年龄从37岁至64岁，诊断为ARVI的女性的组进行研究。将所述制剂开药给上述组，舌下给药，剂量为于一个月内每天两次每次1片。
结果为，该组的患者的疾病处于更轻度的形式：体温未超过38度，没有出现严重的鼻塞和流鼻涕。此外，恢复期比未接受所述制剂的患者短2-5天。

Claims (1)

1.每日10mg至1000mg的量的雄峰幼虫吸附匀浆和每日50ME至100 000ME的量的维生素D或D族维生素和/或其活性代谢物在制造用于预防或治疗病毒性疾病的药物中的用途。
CN201480037596.0A 2013-07-03 2014-07-03 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 Active CN105451749B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2013130302 2013-07-03
RU2013130302/15A RU2564111C9 (ru) 2013-07-03 2013-07-03 Применение адсорбированного гомогената трутневого расплода и витаминов группы d и/или их активных метаболитов для профилактики и лечения острых респираторных заболеваний и гриппа
PCT/RU2014/000487 WO2015002576A1 (ru) 2013-07-03 2014-07-03 Применение адсорбированного гомогената трутневого расплода и витамина d3 или витаминов группы d и/или их активных метаболитов для профилактики и лечения вирусных заболеваний

Publications (2)

Publication Number Publication Date
CN105451749A CN105451749A (zh) 2016-03-30
CN105451749B true CN105451749B (zh) 2019-08-06

Family

ID=52144046

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480037596.0A Active CN105451749B (zh) 2013-07-03 2014-07-03 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用

Country Status (10)

Country Link
US (1) US20160136208A1 (zh)
EP (1) EP3017820B1 (zh)
CN (1) CN105451749B (zh)
CA (1) CA2917081C (zh)
EA (1) EA028540B1 (zh)
ES (1) ES2746002T3 (zh)
PL (1) PL3017820T3 (zh)
RU (1) RU2564111C9 (zh)
UA (1) UA116659C2 (zh)
WO (1) WO2015002576A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006131A (es) 2019-12-05 2022-06-17 Magna Int Inc Metodo y configuracion para robotica sin vallas.
RU2739806C1 (ru) * 2020-03-17 2020-12-28 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный аграрный университет" (ФГБОУ ВО Волгоградский ГАУ) Детское питание

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580297A (en) * 1992-09-30 1996-12-03 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Royal jelly
RU2233666C1 (ru) * 2002-12-30 2004-08-10 Пятигорская государственная фармацевтическая академия Таблетки "апилар" на основе трутневого расплода, обладающие анаболическим, актопротекторным действием
CN103153319A (zh) * 2011-05-31 2013-06-12 "Parafarm"有限责任公司 使干骺端区（小梁区）空腔充满钙和预防其钙流失的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
CA2526845A1 (en) * 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
RU2412616C1 (ru) * 2009-11-30 2011-02-27 Общество С Ограниченной Ответственностью "Парафарм" Биологически активная добавка к пище для профилактики заболеваний остеопорозом
RU2491078C2 (ru) * 2011-09-16 2013-08-27 Общество С Ограниченной Ответственностью "Парафарм" Способ приготовления расплода трутневого адсорбированного и его состав
RU2498811C1 (ru) * 2012-04-19 2013-11-20 Общество С Ограниченной Ответственностью "Парафарм" Способ профилактики и лечения остеопороза и переломов костей и препарат для профилактики и лечения остеопороза и переломов костей
RU2497533C1 (ru) * 2012-04-19 2013-11-10 Общество С Ограниченной Ответственностью "Парафарм" Способ и препарат для профилактики и лечения атипичного остеопороза с нормальной или повышенной минерализацией костной ткани с наличием полостных образований в трабекулярных отделах костей (и ему близких состояниях при избыточной массе и метаболическом синдроме)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580297A (en) * 1992-09-30 1996-12-03 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Royal jelly
RU2233666C1 (ru) * 2002-12-30 2004-08-10 Пятигорская государственная фармацевтическая академия Таблетки "апилар" на основе трутневого расплода, обладающие анаболическим, актопротекторным действием
CN103153319A (zh) * 2011-05-31 2013-06-12 "Parafarm"有限责任公司 使干骺端区（小梁区）空腔充满钙和预防其钙流失的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gerry K. Schwalfenberg.A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency.《Mol. Nutr. Food Res》.2010,第55卷(第1期),第96-108页.
Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren;M Urashima等;《American Journal of Clinical Nutrition》;20101231;第91卷(第5期);第1255-1260页
Продукты питания，рецепты;TRUTNEVYI GOMOGENAT;《URL:http://www.edka.ru/food/trutnev-homogenate》;20130119;第1-5页

Also Published As

Publication number Publication date
EP3017820A4 (en) 2017-03-22
PL3017820T3 (pl) 2019-12-31
ES2746002T3 (es) 2020-03-04
US20160136208A1 (en) 2016-05-19
EP3017820A1 (en) 2016-05-11
WO2015002576A1 (ru) 2015-01-08
RU2013130302A (ru) 2015-01-10
CA2917081C (en) 2019-01-15
CN105451749A (zh) 2016-03-30
EP3017820B1 (en) 2019-06-26
CA2917081A1 (en) 2015-01-08
RU2564111C9 (ru) 2016-03-20
EA201501173A1 (ru) 2016-06-30
RU2564111C2 (ru) 2015-09-27
UA116659C2 (uk) 2018-04-25
EA028540B1 (ru) 2017-11-30

Similar Documents

Publication Publication Date Title
Drake et al. Caffeine effects on sleep taken 0, 3, or 6 hours before going to bed
Poyatos et al. Oral administration of cannabis and Δ-9-tetrahydrocannabinol (THC) preparations: a systematic review
Shergis et al. 12-month randomised controlled trial of ginseng extract for moderate COPD
CN105451749B (zh) 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用
Temviriyanukul et al. Analysis of phytonutrients, anti-mutagenic and chemopreventive effects of tropical fruit extracts
CN104189819B (zh) 一种用于调理情绪健康的中药制剂
CN104223073B (zh) 一种助眠的食品、保健品或药物组合物
Sakhanda et al. Assortment of herbal medicines of the treatment of cardiovascular diseases
Ranade et al. Cannabis (Bhanga) in Classical Text of Ayurveda: An Evidence-Based Rationale
CN108785407A (zh) 一种中草药组合物及其制备方法与用途
CN107874241A (zh) 一种改善睡眠的保健食品及其制备方法
Davis et al. ACTIVATED CHARCOAL: A CONSIDERATION FOR USE IN PRIMARY CARE PRACTICE OF ADVANCED PRACTICE NURSES.
Jaggernauth et al. Datura poisoning in Trinidad: a case report
CN107243010A (zh) 血红素在改善睡眠障碍的药物及保健食品中的应用
Jani et al. Management of COVID-19 by Ayurveda protocol-A Case Series
Frei H1N1-Influeza Epidemic 2011: Experiences with Polarity Analysis
JP2009263384A (ja) Ｉ型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬
Ivker Cannabis for chronic pain: A proven prescription for using marijuana to relieve your pain and heal your life
Ramirez et al. Impact of herbal supplements nowadays: an overview
US10946059B2 (en) Formulation containing an extract of Alpinia galanga, a process for the preparation thereof, and uses thereof
Camille et al. Datura Poisoning in Trinidad: A Case Report
Mwita Amitraz poisoning in a patient from rural Africa
Park et al. Age‐related off‐label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan
Simón et al. 5PSQ-023 Adequate digoxin dosage in patients with digitalis toxicity
US20130028992A1 (en) Herbal-Based Solution for Treating Symptoms of Nasal Conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant